Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2017 05/22/2017 05/23/2017 05/24/2017 05/25/2017 Date
152.34(c) 154.47(c) 155.17(c) 155.73(c) 153.19(c) Last
905 145 593 997 801 852 572 657 674 543 Volume
-1.86% +1.40% +0.45% +0.36% -1.63% Change
More quotes
Financials ($)
Sales 2017 109 M
EBIT 2017 -472 M
Net income 2017 -484 M
Finance 2017 410 M
Yield 2017 -
Sales 2018 411 M
EBIT 2018 -252 M
Net income 2018 -249 M
Finance 2018 317 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 72,1x
EV / Sales2018 19,3x
Capitalization 8 252 M
More Financials
Company
TESARO, Inc. engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and consists of the following portfolio: Rolapitant IV and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010... 
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
05/25 Tesaro Announces Presentations of Abstracts at the 2017 American Society of C..
05/23 TESARO : National Survey Shows Resource, Emotional and Support Needs of the Ovar..
05/22 National Survey Shows Resource, Emotional and Support Needs of the Ovarian Ca..
05/12 TESARO,INC. (NASDAQ : TSRO) Files An 8-K Submission of Matters to a Vote of Secu..
05/12 TESARO, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/12 TESARO : Partners With Clinigen to Initiate European Managed Access Program for ..
05/11 TESARO Partners With Clinigen to Initiate European Managed Access Program for..
05/10 OPKO Health Reports 2016 Financial and Operating Results
05/09 TESARO : Management's Discussion and Analysis of Financial Condition and Results..
05/09 TESARO : reports 1Q loss
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Latest Tweets
03:54aTesaro Announces Presentations of Abstracts at the 2017 American Society of C.. 
12:44a$TSRO: Tesaro announced the presentation of three ZEJULA (niraparib) abstract.. 
05/25TESARO Inc $TSRO Position Increased by Profund Advisors LLC  
05/25On The Fly: Top five analyst initiations $TSRO $LYV $DXC $COL $PODD
3
05/25+Initiations 5/25: $NCSM $NEWR $NOW $NPTN $PM $PODD $PRAA $PSX $TSRO $VIVE -.. 
More tweets
Qtime:20
News from SeekingAlpha
05/22 Tesaro (TSRO) Bank of America Merrill Lynch 2017 Health Care Conference - Sli..
05/19 Johnson & Johnson Lays Out Its Battle Plan
05/15 GILEAD : Dead Money, Time For Investors To Move On
05/10 TESARO's (TSRO) CEO Lonnie Moulder on Q1 2017 Results - Earnings Call Transcr..
05/09 TESARO Q1 loss narrows; U.S. Zejula launch at $89M run rate
Advertisement
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Full-screen chart
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 182 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson Chief Financial Officer & Executive Vice President
Martin H. Huber Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC13.91%8 320
AMGEN, INC.6.31%112 531
CELGENE CORPORATION0.86%90 349
GILEAD SCIENCES, INC.-9.85%84 101
REGENERON PHARMACEUTIC..24.83%48 999
ACTELION LTD26.30%30 824
More Results